ICCM NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Icecure Medical · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 2.89 USD
-6.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -73.7% below the Trend Line and sits at 1.9% of its 52-week range. The latest completed week returned -6.2%, after a -46.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 10d.

Setup score 13 out of 100
Latest Close 2.89 USD 31 Jul 2026
1W Return -6.2% latest completed week
4W Return -46.1% short-term follow-through
12W Return -59.9% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.0x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -6.2% Latest completed week; four-week move -46.1%. Indicator stack 0/52 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 38.69% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 52/100 71 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -73.7% below the Trend Line and sits at 1.9% of its 52-week range. The latest completed week returned -6.2%, after a -46.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.0x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0112-week average 0.02

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -46.1% over four weeks, -59.9% over 12 weeks, and -90.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-6.2%
4W-46.1%
12W-59.9%
26W-84.2%
52W-90.5%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.19Latest activity-pressure read.
Pressure change66.7%Four-week change in activity pressure.
Leadership-84.78Latest relative-leadership reading.
RS change-11.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 76% Model confidence 73%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength57/100Blend of value, momentum, and quality. Underlying universe rank 44; rank 1 is best.
Value53/100Relative valuation strength. Underlying universe rank 48; rank 1 is best.
Quality51/100Profitability and accounting quality. Underlying universe rank 50; rank 1 is best.
Momentum53/100Medium-term price momentum. Underlying universe rank 48; rank 1 is best.
Growth53/100Revenue and earnings growth. Underlying universe rank 48; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
36.5%
Gross profit retained from each unit of revenue.
Operating margin
-439.9%
Operating profit retained from revenue.
Free-cash-flow margin
-425.6%
Free cash flow generated from revenue.
Return on invested capital
-2270.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
8.9%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 71 relevant articles.

12 positive · 50 neutral · 9 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-93.1%Distance below the 52-week high.
13-week volatility40.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2615 weeks finished lower.
Best week+125.9%Week of 19 Jun.
Worst week-45.2%Week of 12 Jun.
Latest week-6.2%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains3
Flat weeks1
Modest losses2
Sharp losses13
Recent vol40.1%13-week weekly-return volatility.
Base vol22.3%52-week weekly-return volatility.
Up/down split17/34Count of positive and negative weeks in the 52-week window.
Average skew15.0% / -11.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape15/100

Trend, activity pressure, participation, and risk combine to a 15/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 38.69%

Next-week expectancy is negative with a 38.69% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors53/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 71 relevant articles.

IceCure's tumor-freezing treatment proposed as breast surgery alternative Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.89 USD-6.2%10.99 USD25.55 USD-0.19-84.78310.5KOff
24 Jul 20263.08 USD-15.6%11.52 USD25.75 USD-0.15-84.24435.1KOff
17 Jul 20263.65 USD0.0%12.09 USD25.97 USD-0.18-82.25451.0KOff
10 Jul 20263.65 USD-31.9%12.64 USD26.17 USD-0.26-83.522.3MOff
3 Jul 20265.36 USD-10.1%13.18 USD26.40 USD-0.57-76.141.2MOff
26 Jun 20265.96 USD10.4%13.69 USD26.58 USD-0.71-74.0240.6MOff
19 Jun 20265.40 USD125.9%14.21 USD26.77 USD-0.85-78.13157.0MOff
12 Jun 20262.39 USD-45.2%14.69 USD26.96 USD-0.90-90.32614.5KOff
5 Jun 20264.37 USD-33.6%15.33 USD27.18 USD-0.87-82.4426.4MOff
29 May 20266.57 USD-6.8%15.87 USD27.38 USD-0.95-75.442.6MOff
22 May 20267.05 USD2.3%16.36 USD27.55 USD-0.97-73.624.5MOff
15 May 20266.89 USD-4.2%16.93 USD27.71 USD-1.05-74.582.3MOff
8 May 20267.20 USD-20.3%17.52 USD27.91 USD-1.11-74.193.1MOff
1 May 20269.04 USD7.6%18.15 USD28.11 USD-1.11-66.692.7MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.